Type 2 diabetes associated with increased risk of colorectal cancer
the ONA take:
According to a new study published in the journal Diabetes Care, researchers from the Utrecht University Institute of Pharmaceutical Sciences in Utrecht, the Netherlands, have found that type 2 diabetes is associated with a moderately increased risk of colorectal cancer.
For the study, researchers sought to investigate the risk of colorectal cancer in patients with type 2 diabetes and to assess whether treatment stage and duration of obesity affect that risk.
They identified 2,759 patients with type 2 diabetes and colorectal cancer after a median follow-up of 4.5 years from the Clinical Practice Research Datalink. All patients were on at least one prescription drug for type 2 diabetes. Results showed that type 2 diabetes was linked with a 1.3-fold increased risk for developing colorectal cancer (HR = 1.26; 95% CI: 1.18 - 1.33).
There was no association between treatment stages and colorectal cancer risk, but patients with obesity for 4 to 8 years (HR = 1.19; 95% CI: 1.06 - 1.34) and those with obesity for more than 8 years (HR = 1.28; 95% CI: 1.11 - 1.49) had a significantly increased risk of colorectal cancer.
The findings suggest that patients with type 2 diabetes, especially those who have been obese for 4 or more years, have an increased risk for developing colorectal cancer.
Type 2 diabetes is associated with a moderately increased risk of colorectal cancer.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|